Pharmaceutical Suppliers: Multi-product Tender consultation (text extract)

This is the text extract for Pharmaceutical Suppliers: Multi-product Tender consultation, browse documents here.

21 August 2009

2009/10 Multi-product Tender

PHARMAC is seeking feedback from pharmaceutical suppliers and interested parties on: · · · A proposal to tender certain pharmaceuticals for sole supply; The draft process and terms and conditions for the Invitation to Tender 2009/10; and Commercial Proposals as an alternative to tendering.

PHARMAC welcomes all feedback.

ALTERNATIVE COMMERCIAL PROPOSAL RESPONSES DUE BY

5 PM, FRIDAY 25 SEPTEMBER 2009

AND ALL OTHER CONSULTATION RESPONSES BY

5 PM, FRIDAY 2 OCTOBER 2009

Feedback should be provided by submitting an email, fax or letter to: Yvonne Chen Tender Analyst PHARMAC PO Box 10-254 Wellington 6143 Email: yvonne.chen@pharmac.govt.nz Fax: (04) 460 4995 DDI: (04) 916 7556

All feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC, and will be considered by the PHARMAC Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal. Details of the proposed 2009/10 multi-product tender In general, the proposed Tender process would be similar to the 2008/09 Tender. In addition to Alternative Commercial Proposals that are discussed later, we seek comments on the approach outlined in the following pages, in particular on: · · · The proposed process; The proposed timetable; An indication of any pharmaceuticals, whether or not included in Schedule Two of the draft Invitation to Tender, that you think would be inappropriate to tender, and the reasons for that view; An indication of any pharmaceuticals, whether or not they are included in Schedule Two of the draft Invitation to Tender, that you consider should be tendered, and the reasons for that view. If you wish, you may provide a non-binding confidential

A300336 - qA15909

· ·

indication of the price or price range that you might be able to offer for a line item or group of line items you wish to have tendered; Any contractual constraints or patent protection that could restrict PHARMAC from awarding a Tender on a particular pharmaceutical; For Hospital pharmaceuticals, feedback on the appropriate Discretionary Variance Limit for each pharmaceutical, in the event that a 1% Discretionary Variance Limit is considered clinically unacceptable; and feedback on any unresolved Tender Bid(s) from previous tenders that you consider should remain open for acceptance.

We seek comments on all sections of the draft Invitation to Tender. The draft Invitation to Tender is based on the format of the Invitation to Tender dated 23 December 2008 for community supply and/or hospital supply. Alternative Commercial Proposals PHARMAC seeks any Alternative Commercial Proposals (ACPs) to tendering that you may wish to submit by 5pm, Friday 25 September 2009. An ACP, for example, may offer price reductions on one set of pharmaceuticals in return for PHARMAC agreeing to defer tendering on another group of pharmaceuticals for a period. Please note the following points with regard to ACPs for both the community and DHB Hospital markets: · · Proposals may include more than one line item and may include pharmaceuticals not listed in Schedule Two of the draft Invitation to Tender; Proposals may seek PHARMAC’s agreement to defer tendering or application of reference pricing as a result of a Tender award for a period of time for any pharmaceutical, whether or not it is listed in Schedule Two of the draft Invitation to Tender; Proposals must not involve PHARMAC agreeing to award Sole Subsidised Supply in the community but may include the awarding of Hospital Supply Status for DHB Hospital pharmaceuticals; PHARMAC reserves the right: o not to accept any proposal; and/or o not to provide reasons for the acceptance or non-acceptance of any proposal; and/or o to enter into an agreement or arrangement that differs in a material respect from that envisaged in this letter; and PHARMAC may decide not to consider any proposal that is submitted after Friday 25 September 2009.

Tender Timelines This year we are proposing to bring forward the tender timelines by one month, this would result in the final Invitation to Tender being released in late November, consequently the closing date for tender submissions would move forward to the last week of January. The proposed timeline is outlined in the following table:

A300336 - qA15909

Proposed Key Dates and Timeframes for the 2009/10 Tender:

Date August/September 2009 25 September 2009 (5pm) 2 October 2009 (5pm) October 2009 Event Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender. Final date for receipt of Alternative Commercial Proposals to tendering by PHARMAC. Final date for all consultation to be received. PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC’s Decision Criteria and enters into provisional contracts with suppliers where appropriate. Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list. Consultation and Board decisions on Alternative Commercial Proposals. Issuing of the 2009/10 Invitation to Tender. Invitation to Tender closes. Board decisions on the first Tender winners announced. End of the sole supply period for all pharmaceuticals where a Tender is awarded from the 2009/10 Tender. Terms after the End Date may apply.

October 2009 October/November 2009 Late November 2009 Late January 2010 From February 2010 30 June 2013

Depending on the feedback received via consultation, PHARMAC proposes to move forward the tender timelines by a further month in the 2010/11 Tender, with the approximate timeline outlined in the table below: Proposed Key Dates and Timeframes for the 2010/11 Tender:

Date July/August 2010 August 2010 September 2010 September 2010 Event Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender. Final date for receipt of Alternative Commercial Proposals to tendering by PHARMAC. Final date for all consultation to be received. PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC’s Decision Criteria and enters into provisional contracts with suppliers where appropriate. Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list. Consultation and Board decisions on Alternative Commercial Proposals. Issuing of the 2010/11 Invitation to Tender. Invitation to Tender closes. Board decisions on the first Tender winners announced.

September 2010 September/October 2010 Late October 2010 Late December 2010 From January 2011

A300336 - qA15909

Since inception, PHARMAC’s annual multi-product tender has generally been released at the end of December of each year with the closing date for tender submissions in late February or early March of the following year. Each year the Invitation to Tender includes a number of products coming off Sole Subsidised Supply at the end of June of the following year. Previous tender timelines have meant that April is the earliest month that the PHARMAC Board (or Chief Executive, under delegated authority) is able to make tender decisions that would involve a brand change. A number of suppliers have commented in the past that the existing timelines, on occasion, make it difficult for the incumbent (Sole Subsidised) supplier to manage its inventory while tender decisions are pending an announcement. PHARMAC considers that moving forward the tender timelines by one month in the 2009/10 Tender and by a further month for the 2010/11 Tender may help to alleviate a number of stock management issues that have previously been experienced by suppliers during the transition period of a brand switch. Should this proposal be implemented, suppliers could be notified as early as January of tender decisions from the 2010/11 Tender. Any feedback regarding the proposed tender timelines should be received by PHARMAC no later than 5pm, 2 October 2009. Draft Invitation to Tender PHARMAC seeks feedback on the terms and conditions of the draft Invitation to Tender to be considered by the PHARMAC Board at its November 2009 meeting. Attached is the draft list of products to be tendered (Schedule Two). A complete copy of the draft Invitation to Tender is available on our website (www.pharmac.govt.nz), including the terms of supply. PHARMAC proposes that, if a Tender Bid was accepted by the PHARMAC Board (or the Chief Executive under delegated authority), it would be subject to the terms and conditions of the draft Invitation to Tender. The draft Invitation to Tender is still under development and may change before it is taken to the Board for approval and subsequently issued. PHARMAC is seeking feedback on the composition of the draft Invitation. At this stage, but depending on the extent of any changes, PHARMAC does not intend to send out any further drafts for consultation. Any feedback regarding the draft Invitation should be received by PHARMAC no later than 5pm, 2 October 2009. Late feedback may not be considered. Consultation feedback received by the due date will be presented to the PHARMAC Board for consideration before it makes its decision. The draft Invitation to Tender comprises the following sections: Schedule 1: Schedule 2: Definitions and interpretation; The list of pharmaceuticals proposed to be tendered. Please note that the market data for the year ended 30 June 2009 provided in this Schedule has not yet been finalised; however finalised data would be captured in the final Invitation to Tender. The final list of pharmaceuticals would be released with the Invitation to Tender following Board approval (please note that the list may change following consultation, and that you may provide feedback on the inclusion of additional pharmaceuticals after the Invitation to Tender has been issued, and any such feedback would be considered by the Board (or Chief

A300336 - qA15909

Schedule 3: Schedule 4: Schedule 5: Schedule 6:

Executive) before making a final decision on any Tender Bid provided that the feedback is given before the tender close date in early 2010); Tender process (for both hospital and community Tenders); Contract terms for Sole Subsidised Supply and/or Hospital Supply Status; Additional contract terms for Sole Subsidised Supply; Additional contract terms for Hospital Supply Status.

The main changes are: Audit PHARMAC proposes to amend clause 3 of Schedule 4 of the Invitation to Tender to include a provision that would provide an auditor authorised by PHARMAC, the access to the premises of any wholesaler or other distributors. Withdrawal or suspension of Sole Supply Status and/or Hospital Supply Status PHARMAC proposes to add a provision in clause 1.3 and clause 1.4 of Schedule 5; and clause 1.7 and clause 1.8 of Schedule 6 of the Invitation that would provide PHARMAC with the option to withdraw or suspend Sole Supply Status and/or Hospital Supply Status for other forms or strengths of the same chemical if PHARMAC has exercised its rights to withdraw or suspend Sole Supply Status under clause 1.3 or clause 1.4 of Schedule 5 and/or Hospital Supply Status under clause 1.7 and clause 1.8 of Schedule 6 of the Invitation to Tender. Price PHARMAC proposes to add a provision both in clause 3 of Schedule 5 and Schedule 6 of the Invitation to Tender that clarifies the expectation that the price offered by a supplier through the tender process would incorporate any costs incurred following the subsequent delisting of the product.

Electronic Tender (eTender) system The final 2009/10 Invitation to Tender will be distributed via the eTender system and a test of supplier’s email addresses will occur in November 2009. Please ensure that you respond by 5pm, 2 October 2009 with updated addresses if your email has changed. Unresolved Tender Bids PHARMAC would review any unresolved Tender Bids from the Invitation to Tender dated 21 December 2007 (2007/08 Tender) and the Invitation to Tender dated 23 December 2008 (2008/09 Tender) prior to issuing the 2009/10 Invitation to Tender. Should any unresolved Tender Bids be declined, PHARMAC would consider re-tendering those pharmaceuticals when the Invitation to Tender is issued in November 2009. Unresolved Tender Bids have not been included in the draft pharmaceutical list. PHARMAC seeks comments from suppliers that consider that any unresolved Tender Bid(s) should remain open for acceptance by 5pm, 2 October 2009.

A300336 - qA15909

Reference Pricing Reference pricing is based on the classification of pharmaceuticals into Therapeutic Subgroups. A Therapeutic Subgroup is defined as a set of pharmaceuticals that produce the same or similar therapeutic effect in treating the same or similar condition(s). The draft list contains pharmaceuticals that belong in an existing Therapeutic Subgroup. In some cases, PHARMAC may be considering tendering more than one pharmaceutical in a Therapeutic Subgroup. Where this is the case it gives rise to a number of scenarios including: 1) It is possible that awarding Sole Subsidised Supply to one pharmaceutical could result in changes to the subsidies for other pharmaceuticals in the same Therapeutic Subgroup; and/or 2) Where more than one pharmaceutical in a Therapeutic Subgroup is included on the list, PHARMAC may award Sole Subsidised Supply to each pharmaceutical (and therefore not apply reference pricing in the usual way) or may only award Sole Subsidised Supply to one pharmaceutical and apply reference pricing to the others. Such scenarios could give rise to new or increased manufacturer surcharges. We ask that you consider any clinical considerations associated with such scenarios. Products not currently listed on the Pharmaceutical Schedule The following is a list of chemicals included in Schedule Two that are not currently listed on the Pharmaceutical Schedule: · · · · · · · Abacavir Sulphate with Lamivudine and Zidovudine Bacillus Calmette-Guerin Vaccine Bisoprolol Fumarate Escitalopram Esomeprazole Gemfibrozil Glimepiride · · · · · · · Ketamine Hydrochloride Nizatidine Pramipexole Hydrochloride Rabeprazole Risedronate Sodium Sertraline Topotecan

We note that funding of escitalopram, gemfibrozil, ketamine hydrochloride, pramipexole hydrochloride, rabeprazole, and sertraline have been considered by the Pharmacology and Therapeutic Advisory Committee (PTAC) or the relevant Subcommittee of PTAC; however further review, and the review of the remainder of the chemicals in the list above may be considered by PTAC and/or PTAC Subcommittee, after tender bids have been received. Please note the decision to fund the chemicals listed above would largely depend on the pricing of Tender Bids against that of alternative chemicals already listed on the Pharmaceutical Schedule. We note that PHARMAC would be willing to support priority assessment from Medsafe to applications submitted as a result of the tender process where we consider it to be appropriate.

A300336 - qA15909

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Abacavir Sulphate Oral liq 20 mg per ml Tab 300 mg Abacavir sulphate with lamivudine Tab 600 mg with lamivudine 300 mg Abacavir Sulphate with Lamivudine and Zidovudine Tab 300 mg with lamivudine 150 mg, and zidovudine 300 mg Acebutolol Cap 100 mg Cap 200 mg Tab 400 mg 60,820 130,884 $5,778 $20,863 $0.0950 $0.1594 C H C H C H 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

42,936 35,393

$17,890 $270,167

$0.4167 $7.6333

C H C H

1% 1%

60,587

$1,272,327

$21.0000

C H

Not currently listed on the Pharmaceutical Schedule

Alprazolam Tab 250 mcg Tab 500 mcg Tab 1 mg Amiodarone Hydrochloride Inj 50 mg per ml, 3 ml Amoxycillin Cap 250 mg Cap 500 mg Amsacrine Inj 75 mg Apomorphine Hydrochloride Inj 10 mg per ml Arsenic trioxide Inj 10 mg Ascorbic Acid Eye drops 10% Inj 500 mg per 5 ml Tab 50 mg Tab 100 mg Tab 250 mg 1,329,567 $45,870 $0.0345 H H C H C H C H 1% 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

327,241 282,290 84,739

$21,271 $24,277 $13,304

$0.0650 $0.0860 $0.1570

C C C

4,793

$29,161

$6.0840

C H

1,728,107 10,097,812

$59,793 $550,331

$0.0346 $0.0545

C H C H

1% 1%

H PCT 1%

2,157

$21,756

$10.0860

C H

H PCT 1%

Aspirin Tab 100 mg 102,957,010 $1,750,269 $0.0170 C

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Aspirin Tab dispersible or soluble 300 mg Atorvastatin Tab 10 mg 4,827,918 $648,389 $0.1343 *

+ C A Special Authority for the Manufacturers Price currently exists. The total cost, accounting for patients with Special Authority, was $2,878,089 for the year ended 30 June 2009 A Special Authority for the Manufacturers Price currently exists. The total cost, accounting for patients with Special Authority, was $5,953,386 for the year ended 30 June 2009 A Special Authority for the Manufacturers Price currently exists. The total cost, accounting for patients with Special Authority, was $10,440,546 for the year ended 30 June 2009 This was recently listed on the Pharmaceutical Schedule. A Special Authority for the Manufacturers Price currently exists

Units

Cost

Unit Subsidy

DV Limit

Comments

3,077,961

$66,176

$0.0215

Tab 20 mg

6,791,393

$1,329,076

$0.1957

+ C

Tab 40 mg

8,504,025

$2,307,142

$0.2713

+ C

Tab 80 mg

$0.5427

+ C

Azathioprine Inj 50 mg Tab 50 mg Bacillus Calmette-Guérin (BCG) Vaccine Inj containing equal to or greater than 500 million CFU H PCT 1%

Not currently listed on the Pharmaceutical Schedule. Tender agreement would be for non-vaccine use and may be subject to a Special Authority restriction

30 3,637,906

$1,390 $909,477

$46.3300 $0.2500

C H C H

1% 1%

Beclomethasone Dipropionate Metered aqueous nasal spray, 50 mcg per dose Metered aqueous nasal spray, 100 mcg per dose Bisacodyl Tab 5 mg Bisoprolol fumarate Tab 2.5 mg C

Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to a Special Authority Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to a Special Authority Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to a Special Authority

12,722,366 47,280,695

$149,488 $581,553

$0.0118 $0.0123

C H C H

1% 1%

1,551,489

$39,485

$0.0255

C H

Tab 5 mg

Tab 10 mg

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Bleomycin sulphate Inj 15,000 iu Budesonide Metered aqueous nasal spray, 50 mcg per dose Metered aqueous nasal spray, 100 mcg per dose Bumetanide Tab 1 mg Bupivacaine Hydrochloride Inf 0.125%, 100 ml theatre pack Inf 0.125%, 200 ml theatre pack Inf 0.25%, 100 ml theatre pack Inj 0.5%, 8% glucose, 4 ml Busulphan Tab 2 mg Caffeine Citrate Inj 10 mg per ml, 2.5 ml Oral liq 10 mg per ml Calcipotriol Crm 50 mcg per g (pack size 30 g or less) Crm 50 mcg per g (pack size greater than 30 g) Oint 50 mcg per g (pack size 30 g or less) 1,419,618 1,419,618 1,507,289 $821,817 $821,817 $1,043,044 $0.5789 $0.5789 $0.6920 C H C H C H 1% 1% 1%

Volume is aggregated for all pack sizes of calcipotriol cream Volume is aggregated for all pack sizes of calcipotriol cream Volume is aggregated for all pack sizes of calcipotriol ointment Volume is aggregated for all pack sizes of calcipotriol ointment Volume is aggregated for all pack sizes of calcipotriol solution Volume is aggregated for all pack sizes of calcipotriol solution

Units

Cost

Unit Subsidy

DV Limit

Comments

5,268,675 30,304,478

$61,907 $395,473

$0.0118 $0.0131

C H C H

1% 1%

836,929

$136,922

$0.1636

C H

H H H 503 $2,465 $4.9000 C H

1% 1% 1% 1%

7,423

$3,555

$0.4789

H H

1% 1%

Oint 50 mcg per g (pack size greater than 30 g)

1,507,289

$1,043,044

$0.6920

C H

Soln 50 mcg per ml (pack size 30 ml or less)

313,503

$217,153

$0.6927

C H

Soln 50 mcg per ml (pack size greater than 30 ml)

313,503

$217,153

$0.6927

C H

Captopril Oral liq 5 mg per ml Tab 12.5 mg Tab 25 mg Tab 50 mg Carmustine Inj 100 mg H 1% 85,273 505,495 830,687 637,696 $45,814 $10,514 $22,262 $24,232 $0.5373 $0.0208 $0.0268 $0.0380 C H C H C H C H 1% 1% 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Cefaclor Monohydrate Cap 250 mg Grans for oral liq 125 mg per 5 ml Cetomacrogol Crm BP Chlorambucil Tab 2 mg Cholecalciferol Tab 1.25 mg (50,000 iu) Cilazapril Tab 0.5 mg Tab 2.5 mg Tab 5 mg Cilazapril with Hydrochlorothiazide Tab 5 mg with Hydrochlorothiazide 12.5 mg Ciprofloxacin Inj 2 mg per ml, 100 ml Cisplatin Inj 10 mg Inj 50 mg Inj 100 mg Cladribine Inj 1 mg per ml, 10 ml Inj 2 mg per ml, 5 ml Clarithromycin Tab 250 mg Clindamycin Inj phosphate 150 mg per ml, 4 ml Clopidogrel Tab 75 mg Clotrimazole Pessaries 100 mg with applicator(s) Pessaries 500 mg with applicator Vaginal crm 1% with applicators Vaginal crm 2% with applicators 1,914,684 1,086,351 $79,323 $149,373 $0.0414 $0.1375 C C C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

3,894,014 10,276,124

$1,125,370 $402,824

$0.2890 $0.0392

C H C H

1% 1%

12,146,581

$85,026

$0.0070

85,751

$76,661

$0.8940

C H

1,176,907

$1,015,082

$0.8625

C H

14,646,190 17,316,642 16,520,567

$1,074,054 $2,534,002 $3,546,415

$0.0733 $0.1463 $0.2147

C C C

17,897,458

$4,026,928

$0.2250

H PCT 1% H PCT 1% H PCT 1%

Not currently listed on the Pharmaceutical Schedule

H PCT 1% H PCT 1%

86,986

$48,153

$0.5536

C H

1,141

$22,192

$19.4500

C H

1,820,845

$2,276,056

$1.2500

C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Coal Tar Soln BP $0.0730 C

There are two different subsidies, unit subsidy reflects the subsidy of the fully funded product. Market information unavailable

Units

Cost

Unit Subsidy

DV Limit

Comments

Codeine Phosphate Tab 15 mg Tab 30 mg Tab 60 mg Colchicine Tab 500 mcg - 600 mcg Colistin Sulphomethate Inj 150 mg Compound Electrolytes Powder for soln for oral use Cyclophosphamide Tab 50 mg Cyclosporin A Cap 25 mg Cap 50 mg Cap 100 mg Oral liq 100 mg per ml Cytarabine Inj 100 mg Inj 500 mg Inj 1 g Inj 2 g Dacarbazine Inj 50 mg Inj 200 mg Dactinomycin (actinomycin D) Inj 0.5 mg Daunorubicin Inj 20 mg Desferrioxamine Mesylate Inj 500 mg 22,093 $218,721 $9.9000 C H 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% $16.0000 $19.0720 $42.6500 C H C H C H H 1% 1% 1% 1% 1,032,971 280,201 488,652 16,189 $1,756,051 $948,985 $3,310,031 $122,188 $1.7000 $3.3868 $6.7738 $7.5476 C H C H C H C H 1% 1% 1% 1% 88,044 $45,272 $0.5142 C H 1% 791,686 $226,422 $0.2860 C 7,452 $484,380 $65.0000 C H 1% 3,618,128 $347,340 $0.0960 C H 1% 4,033,866 18,209,124 1,785,587 $221,863 $1,547,776 $330,334 $0.0550 $0.0850 $0.1850 C H C H C H 1% 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Dexamethasone Sodium Phosphate Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Dexamphetamine Sulphate Tab 5 mg Dextrose with Electrolytes Soln with electrolytes 90,789,984 $604,661 $0.0067 C

Sole supply would only be awarded to a range of flavours

Units

Cost

Unit Subsidy

DV Limit

Comments

31,713 76,573

$136,366 $474,753

$4.3000 $6.2000

C H C H

1% 1%

636,761

$108,249

$0.1700

C H

Dobutamine Inj 12.5 mg per ml, 20 ml Domperidone Tab 10 mg 6,579,837 $256,614 $0.0390 C

A Special Authority for full subsidy currently exists. The Special Authority would be removed should a tender be awarded

Doxazosin Mesylate Tab 2 mg Tab 4 mg Emtricitabine Cap 200 mg Ephedrine Sulphate Inj 30 mg per ml, 1 ml Ergometrine Maleate Inj 500 mcg per ml, 1 ml Ergotamine Tartrate with Caffeine Tab 1 mg with caffeine 100 mg Escitalopram Tab 10 mg Tab 20 mg C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

9,601,118 8,384,024

$438,771 $507,401

$0.0457 $0.0605

C H C H

1% 1%

124,667

$1,276,590

$10.2400

C H

1,023

$2,373

$2.3200

C H

423,371

$131,245

$0.3100

C H

Esomeprazole Inj 40 mg Tab 20 mg Tab 40 mg C H C H C H 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Etoposide Cap 50 mg Cap 100 mg 7,910 554 $134,759 $18,876 $17.0365 $34.0730 C H C H 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Etoposide Phosphate Inj 100 mg (of etoposide base) Exemestane Tab 25 mg Famotidine Tab 20 mg Tab 40 mg Ferrous Salts Oral liq Tab (short-acting) 3,817,372 $78,638 $0.0206 C H C H 1% 1%

Any iron salt and additives would be considered. Dose range of 60 - 105 mg elemental iron per tablet required Any iron salt and additives would be considered. Dose range of 60 - 105 mg elemental iron per tablet required

Units

Cost

Unit Subsidy

DV Limit

Comments

H PCT 1%

134,667

$785,558

$5.8333

C H

709,966 621,078

$23,003 $28,197

$0.0324 $0.0454

C H C H

1% 1%

Tab (long-acting)

C H

Fluocortolone Caproate with Fluocortolone Pivalate and Cinchocaine Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g 2,353,042 $498,061 $0.2117 C H 1%

All corticosteroids ointments in the antihaemmorrhoidals group are considered as one Tender Item All corticosteroids suppositories in the antihaemmorrhoidals group are considered as one Tender Item

Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg

730,228

$161,867

$0.2217

C H

Fluorouracil Sodium Inj 25 mg per ml, 100 ml Inj 50 mg per ml, 10 ml Inj 50 mg per ml, 20 ml Inj 50 mg per ml, 50 ml Inj 50 mg per ml, 100 ml Fluoxetine Hydrochloride Cap 20 mg Tab dispersible 20 mg, scored Flutamide Tab 250 mg Furosemide Inj 10 mg per ml, 2 ml Inj 20 mg per ml, 2 ml 19,591 $11,559 $0.5900 C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule

H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1%

21,564,650 854,866

$1,051,876 $156,725

$0.0488 $0.1833

C H C H

1% 1%

453,951

$179,311

$0.3950

C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Fusidic Acid Crm 2 % Oint 2 % Gemcitabine Hydrochloride Inj 200 mg Inj 1 g Gemfibrozil Tab 300 mg C H 1%

Not currently listed on the Pharmaceutical Schedule. Capsule form would be considered Not currently listed on the Pharmaceutical Schedule. Capsule form would be considered

Units

Cost

Unit Subsidy

DV Limit

Comments

1,466,886 1,002,501

$386,280 $263,992

$0.2633 $0.2633

C H C H

1% 1%

H PCT 1% H PCT 1%

Tab 600 mg

C H

Gentamicin Sulphate Inj 10 mg per ml, 1 ml Glimepiride Tab 1 mg Tab 2 mg Tab 3 mg Tab 4 mg C H C H C H C H 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

$1.7120

C H

Market information unavailable

Glycerol Liq BP Suppos 3 g or less Suppos greater than 3 g Glyceryl Trinitrate Inj 5 mg per ml, 1 ml Inj 5 mg per ml, 10 ml Haloperidol Inj 5 mg per ml, 1 ml Oral liq 2 mg per ml Tab 500 mcg Tab 1.5 mg Tab 5 mg Hydralazine Inj 20 mg per ml, 1 ml 52 $269 $5.1800 C H 1% 39,565 65,301 1,232,826 258,263 262,642 $67,419 $11,793 $60,778 $19,241 $61,695 $1.7040 $0.1806 $0.0493 $0.0745 $0.2349 C H C H C H C H C H 1% 1% 1% 1% 1% H H 1% 1% 56,472 263,122 $14,683 $65,781 $0.0124 $0.2600 $0.2500 C H C H C H 1% 1% 1%

Market information unavailable

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Hydrocortisone Inj 50 mg per ml, 2 ml Hydrocortisone Butyrate Scalp lotn 0.1% Hydrocortisone with Cinchocaine Oint 5 mg with cinchocaine hydrochloride 5 mg per g C H 1%

Not currently listed in the Pharmaceutical Schedule. All corticosteroids ointments in the antihaemmorrhoidals group are considered as one Tender Item Not currently listed in the Pharmaceutical Schedule. All corticosteroids suppositories in the antihaemmorrhoidals group are considered as one Tender Item

Units

Cost

Unit Subsidy

DV Limit

Comments

6,999

$26,036

$3.7200

C H

3,642,476

$273,914

$0.0752

C H

Suppos 5 mg with cinchocaine hydrochloride 5 mg per g

C H

Hydrocortisone with Lignocaine, Aluminium and Zinc Oint 0.25% with lignocaine hydrochloride 5% aluminium subacet 3.5% and zinc oxide 18% C H 1%

Suppos 0.25% with lignocaine hydrochloride 5% aluminium subacet 3.5% and zinc oxide 18%

C H

Hydrocortisone with Natamycin and Neomycin Crm 1% with natamycin 1% and neomycin sulphate 0.5% Oint 1% with natamycin 1% and neomycin sulphate 0.5% Ibuprofen Oral liq 100 mg per 5 ml Imatinib Mesylate Tab 100 mg 395,319 $15,812,760 $40.0000

+ C H

1,793,319

$526,040

$0.2933

817,977

$239,940

$0.2933

27,842,543

$485,852

$0.0175

C H

Tender agreement may be subject to a Special Authority restriction

Imipramine Hydrochloride Tab 10 mg Tab 25 mg Indomethacin Cap 25 mg Cap 50 mg Cap long-acting 75 mg Suppos 100 mg 291,147 782,475 589,424 39,921 $17,178 $54,382 $78,393 $19,295 $0.0590 $0.0695 $0.1330 $0.4833 C H C H C H C H 1% 1% 1% 1% 496,156 1,579,879 $54,379 $278,059 $0.1096 $0.1760 C H C H 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Ipratropium Bromide Aqueous nasal spray, 0.03% Nebuliser soln, 250 mcg per 1 ml Nebuliser soln, 500 mcg per 2 ml Isoniazid Tab 100 mg Itraconazole Cap 100 mg Ketamine Hydrochloride Inj 10 mg per ml C H 1%

Not currently listed in the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction

Units

Cost

Unit Subsidy

DV Limit

Comments

784,748 78,380 412,284

$331,164 $16,852 $108,225

$0.4220 $0.2150 $0.2625

C C H C H 1% 1%

271,862

$55,732

$0.2050

581,374

$918,571

$1.5800

C H

Inj 50 mg per ml

C H

Inj 100 mg per ml

C H

Lactulose Oral liq 10 g per 15 ml Lamivudine Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 100 mg Tab 150 mg Levodopa with Benserazide Cap 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Cap long-acting 100 mg with benserazide 25 mg Tab dispersible 50 mg with benserazide 12.5 mg Levonorgestrel Tab 30 mcg Tab 750 mcg - 1.5 mg 836,896 56,343 $65,955 $704,288 $0.0788 $12.5000 C C

Bids would be accepted for a tablet within this strength range

182,005,412

$1,210,336

$0.0067

C H

6,220 36,198 327,610 32,249

$2,333 $15,083 $1,673,151 $165,115

$0.3750 $0.4167 $5.1071 $5.1200

C C C C

1,036,487 1,186,884 176,281 567,392 477,398

$82,919 $148,361 $44,070 $96,457 $47,740

$0.0800 $0.1250 $0.2500 $0.1700 $0.1000

C H C H C H C H C H

1% 1% 1% 1% 1%

Lignocaine Viscous solution 2% C H 1%

Not currently listed on the Pharmaceutical Schedule

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Lignocaine Hydrochloride Inj 0.5%, 5 ml Pump spray 10%, 50 ml CFC-free Inj 1%, 5 ml Inj 1%, 20 ml Lignocaine Hydrochloride with Adrenaline Inj 1% with 1:100,000 of adrenaline, 5 ml Inj 1% with 1:200,000 of adrenaline, 20 ml Inj 2% with 1:200,000 of adrenaline, 20 ml Lignocaine with Prilocaine Hydrochloride Crm 2.5% with prilocaine hydrochloride 2.5% 5 g Crm 2.5% with prilocaine hydrochloride 2.5% 30 g Lithium carbonate Tab long-acting 400 mg Lomustine Cap 10 mg Cap 40 mg Loperamide Hydrochloride Tab 2 mg 6,069,760 $174,506 $0.0288 C

Capsule form would be considered

Units

Cost

Unit Subsidy

DV Limit

Comments

11,967

$10,555

$0.8820

C H H

1% 1%

37,078 1,783

$31,146 $8,380

$0.8400 $4.7000

C C

H H H

1% 1% 1%

577 1,335

$4,731 $1,825

$8.2000 $1.3667

C H C H

1% 1%

1,228,213

$197,128

$0.1605

H PCT 1% H PCT 1%

Lopinavir with ritonavir Oral liq 80 mg with ritonavir 20 mg per ml 17,838 $43,703 $2.4500

+ C H

Tender agreement may be subject to a Special Authority restriction Tender agreement may be subject to a Special Authority restriction

Tab 200 mg with ritonavir 50 mg

217,934

$1,334,846

$6.1250

+ C H

Loratadine Oral liq 1 mg per ml Tab 10 mg Lorazepam Tab 1 mg Tab 2.5 mg Magnesium Sulphate Paste (pack size 100 g or less) Malathion Liq 0.5% Shampoo 1% 9,322,516 564,454 $232,597 $53,247 $0.0250 $0.0943 C C 245,281 $9,137 $0.0373 C H 1% 4,504,048 256,352 $113,142 $10,562 $0.0251 $0.0412 C H C H 1% 1% 8,544,371 14,238,914 $311,870 $509,753 $0.0365 $0.0358 C H C H 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Medroxyprogesterone Acetate Tab 2.5 mg Tab 5 mg Tab 10 mg Tab 100 mg Tab 200 mg Melphalan Inj 50 mg Tab 2 mg Menthol Crystals Mercaptopurine Tab 50 mg Mesalazine Tab 400 mg Mesna Tab 400 mg Tab 600 mg Inj 100 mg per ml, 4 ml Inj 100 mg per ml, 10 ml Methadone Hydrochloride Inj 10 mg per ml, 1 ml Tab 5 mg Methotrexate Inj 25 mg per ml, 2 ml Inj 25 mg per ml, 20 ml Inj 10 mg per ml, 0.75 ml prefilled syringe 6,882 23 $63,452 $1,846 $9.2200 $80.2500 C H C H C H 1% 1% 1%

Units

Cost

Unit Subsidy

DV Limit

Comments

221,643 519,805 864,393 44,252 1,192

$15,293 $71,473 $218,115 $46,137 $3,102

$0.0690 $0.1375 $0.2523 $1.0426 $2.6020

C H C H C H C H C H

1% 1% 1% 1% 1%

H PCT 1% 14,585 $18,266 $1.2524 C H 1%

$0.2960

Market information unavailable

212,009

$399,086

$1.8824

C H

2,197,126

$1,087,577

$0.4950

C H

H PCT 1% H PCT 1% H PCT 1% H PCT 1%

35,728 1,975,773

$217,941 $414,912

$6.1000 $0.2100

C H C H

1% 1%

Inj 10 mg per ml, 1 ml prefilled syringe

C H

Inj 10 mg per ml, 1.5 ml prefilled syringe

C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Methotrexate Inj 10 mg per ml, 2 ml prefilled syringe C H 1%

Units

Cost

Unit Subsidy

DV Limit

Comments

Inj 10 mg per ml, 2.5 ml prefilled syringe

C H

Methyl Hydroxybenzoate Powder Methylcellulose Powder Metoclopramide Hydrochloride Oral liq 5 mg per 5 ml $0.0000 C H 1%

Not currently listed on the Pharmaceutical Schedule

$0.4000

Market information unavailable

$0.1400

Market information unavailable

Metronidazole Tab 200 mg Tab 400 mg Miconazole Oral gel 20 mg per g Mitomycin C Inj 2 mg Inj 10 mg Mitozantrone Inj 2 mg per ml, 5 ml Inj 2 mg per ml, 10 ml Morphine Sulphate Cap long-acting 10 mg Cap long-acting 30 mg Cap long-acting 60 mg Cap long-acting 100 mg Cap long-acting 200 mg Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Tab long-acting 10 mg Tab long-acting 30 mg Tab long-acting 60 mg Tab long-acting 100 mg 2,852,145 1,052,319 408,428 304,539 39,285 25,813 11,355 728,273 356,403 175,275 244,268 $513,386 $277,812 $294,068 $239,063 $66,785 $26,691 $10,674 $131,089 $128,305 $126,198 $207,628 $0.1800 $0.2640 $0.7200 $0.7850 $1.7000 $1.0340 $0.9400 $0.1800 $0.3600 $0.7200 $0.8500 C H C H C H C H C H C H C H C H C H C H C H 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% 660,769 $143,717 $0.2175 C H 1% 288,833 1,103,006 $27,439 $193,026 $0.0950 $0.1750 C C

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Morphine Sulphate Tab long-acting 200 mg C H 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

Morphine Tartrate Inj 80 mg per ml, 1.5 ml Inj 80 mg per ml, 5 ml Naloxone Hydrochloride Inj 400 mcg per ml, 1 ml 11,165 $73,689 $6.6000 C H 1%

Min-I-Jet would not be DV Pharmaceutical

26,690 2,560

$107,828 $34,493

$4.0400 $13.4740

C H C H

1% 1%

Naltrexone hydrochloride Tab 50 mg Naproxen Tab long-acting 750 mg Tab long-acting 1,000 mg Naproxen Sodium Tab 275 mg Tab 550 mg Neostigmine Inj 2.5 mg per ml, 1 ml Nizatidine Cap 150 mg Cap 300 mg C C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

84,773

$508,638

$6.0000

C H

893,953 813,534

$178,791 $189,825

$0.2000 $0.2333

C H C H

1% 1%

1,890,518 4,289,670

$94,526 $549,078

$0.0500 $0.1280

C H C H

1% 1%

27,169

$11,031

$0.4060

C H

Nystatin Cap 500,000 u Tab 500,000 u Octreotide (somatostatin analogue) LAR inj 10 mg LAR inj 20 mg LAR inj 30 mg Olanzapine Oradispersible 5 mg Orodispersible 10 mg Tab 2.5 mg Tab 5 mg Tab 10 mg

+ + + + +

230,477 76,029

$53,655 $14,598

$0.2328 $0.1920

C H C H

1% 1%

226 953 744

$400,585 $2,247,889 $2,195,730

$1,772.5000 $2,358.7500 $2,951.2500

C H C H C H

1% 1% 1%

H H H H H

5% 5% 5% 5% 5%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Ondansetron Tab 4 mg Tab 8 mg Tab disp 4 mg Tab disp 8 mg Orphenadrine Citrate Tab 100 mg Oxybutynin Oral liq 5 mg per 5 ml Tab 5 mg Oxycodone Hydrochloride Cap 5 mg Cap 10 mg Cap 20 mg Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 2 ml Oral liq 5 mg per 5 ml Tab controlled-release 5 mg Tab controlled-release 10 mg Tab controlled-release 20 mg Tab controlled-release 40 mg Tab controlled-release 80 mg Pantoprazole Inj 40 mg Tab 20 mg Tab 40 mg Paracetamol Suppos 125 mg Suppos 250 mg Suppos 500 mg Paraffin Liquid with Soft White Paraffin Eye oint with soft white paraffin Paraldehyde Inj 5 ml 219 $65,700 $300.0000 C H 1% 101,341 $105,105 $1.0371 C 66,981 43,621 129,304 $25,084 $31,407 $53,015 $0.3745 $0.7200 $0.4100 C H C H C H 1% 1% 1% 4,351,274 7,307,110 $348,102 $876,853 $8.7500 $0.0800 $0.1200 C H C H C H 1% 1% 1% 1,039,973 695,650 372,631 22,764 21,769 715,606 640,801 1,415,423 879,265 303,822 139,168 $147,156 $194,086 $182,030 $65,560 $125,389 $32,059 $240,621 $788,391 $832,224 $505,712 $403,796 $0.1415 $0.2790 $0.4885 $2.8800 $5.7600 $0.0448 $0.3755 $0.5570 $0.9465 $1.6645 $2.9015

+ C H + C H + C H

Units

Cost

Unit Subsidy

DV Limit

Comments

30,087 112,932 15,985 6,477

$51,689 $191,363 $27,462 $13,233

$1.7180 $1.6945 $1.7180 $2.0430

C H C H C H C H

1% 1% 1% 1%

1,436,969

$266,414

$0.1854

C H

612,575 5,876,883

$65,272 $526,451

$0.1066 $0.0896

C H C H

1% 1%

1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1%

C H C H C H

+ C H + C H + C H + C H + C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Paroxetine hydrochloride Tab 20 mg Pentostatin (deoxycoformycin) Inj 10 mg Pethidine Hydrochloride Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 1.5 ml Inj 50 mg per ml, 2 ml Tab 50 mg Tab 100 mg Phenobarbitone Tab 15 mg Tab 30 mg Phenoxymethylpenicillin (Penicillin V) Cap 250 mg Cap 500 mg Grans for oral liq benzathine 125 mg per 5 ml Grans for oral liq benzathine 250 mg per 5 ml Piperacillin Sodium with Tazobactam Sodium Inj 4 g with tazobactam sodium 500 mg Piroxicam Tab dispersible 10 mg Tab dispersible 20 mg Pramipexole Hydrochloride Tab 0.125 mg C H 1%

Units

Cost

Unit Subsidy

DV Limit

Comments

13,646,015

$2,683,716

$0.1967

C H

H PCT 1%

23,247

$24,177

$1.0400 $0.8700

C H C H C H C C

1% 1% 1%

70,243 278,785 105,727

$77,267 $83,636 $42,291

$1.1000 $0.3000 $0.4000

84,843 781,463

$4,018 $38,432

$0.0474 $0.0492

C H C H

1% 1%

555,005 2,342,365 2,061,408 4,896,391

$47,619 $381,805 $34,632 $89,114

$0.0858 $0.1630 $0.0168 $0.0182

C H C H C H C H

1% 1% 1% 1%

41,511 389,484

$2,698 $21,422

$0.0650 $0.0550

C H C H

1% 1%

Tab 0.250 mg

C H

Tab 1 mg

C H

Tab 1.5 mg

C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Prazosin Hydrochloride Tab 1 mg Tab 2 mg Tab 5 mg Prilocaine Hydrochloride Inj, 0.5%, 50 ml Inj, 2%, 5 ml Procarbazine Hydrochloride Cap 50 mg Propylene Glycol Liq Pyridoxine Hydrochloride Tab 25 mg Rabeprazole Tab 10 mg Tab 20 mg $0.0000 C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

401,233 407,528 267,577

$22,188 $28,527 $31,307

$0.0553 $0.0700 $0.1170

C H C H C H

1% 1% 1%

H H

1% 1%

H PCT 1%

$0.0354

Market information unavailable

643,577

$21,882

$0.0340

C H

Rifabutin Cap 150 mg Risedronate sodium Tab 5 mg C H 1%

Not currenty listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currenty listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currenty listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currenty listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction

10,269

$72,975

$7.1063

C H

Tab 30 mg

C H

Tab 35 mg

C H

Tab 150 mg

C H

Rizatriptan benzoate Wafer 10 mg Ropinirole Hydrochloride Tab 0.25 mg Tab 1 mg Tab 2 mg 308,433 710,596 375,380 $29,007 $341,086 $271,346 $0.0940 $0.4800 $0.7229 C H C H C H 1% 1% 1% 130,467 $1,101,141 $8.4400

+ C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Ropinirole Hydrochloride Tab 5 mg Salbutamol Oral liq 2 mg per 5 ml Salicylic Acid Powder Sertraline Tab 50 mg C H 1%

Units

Cost

Unit Subsidy

DV Limit

Comments

75,658

$81,062

$1.0714

C H

1,019,202

$15,288

$0.0150

C H

$0.0755

Market information unavailable

Tab 100 mg

C H

Sirolimus Oral liq 1 mg per ml Tab 1 mg Tab 2 mg Sodium Bicarbonate Powder BP Sodium Chloride Inj 0.9%, 5 ml Inj 0.9%, 10 ml Inj 0.9%, 20 ml Inj 23.4%, 20 ml Sodium Citrate with Sodium Lauryl Sulphoacetate Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Sodium Citro-Tartrate Grans effervescent 4 g sachets Sodium Cromoglycate Eye drops 2% Sodium Fluorescein Inj 100 mg per ml Spironolactone Tab 25 mg Tab 100 mg 5,328,826 1,295,640 $452,950 $281,154 $0.0850 $0.2170 C H C H 1% 1% H 1% 494,850 $195,466 $0.3950 C 1,372,285 $134,778 $0.0982 C 339,630 $206,597 $0.6083 C H 1% 133,175 543,388 102,212 3,735 $30,630 $124,979 $40,169 $19,796 $0.2300 $0.2300 $0.3930 $5.3000 C H C H C H C H 1% 1% 1% 1% $0.0196 C H 1%

Market information unavailable

2,839 83,240 3,572

$23,081 $676,741 $58,081

$8.1300 $8.1300 $16.2600

C H C H C H

1% 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Sulphur Precipitated Suxamethonium Inj 50 mg per ml, 2 ml Tacrolimus Cap 0.5 mg Cap 1 mg Cap 5 mg Temozolomide Cap 5 mg Cap 20 mg Cap 100 mg Cap 250 mg Teniposide Inj 10 mg per ml, 5 ml Tenoxicam Tab 20 mg Terazosin Hydrochloride Tab 1 mg Tab 2 mg Tab 5 mg Testosterone Transdermal patch 2.5 mg per day Tetrabenazine Tab 25 mg Thalidomide Cap 50 mg Thioguanine Tab 40 mg Thiotepa Inj 15 mg Tolcapone Tab 100 mg 116,011 $149,364 $1.2875 C H 1% H PCT 1% 6,434 $25,005 $3.8864 C H 1% H PCT 1% 116,287 $252,301 $2.1696 C H 1% 105,858 $141,140 $1.3333 C H 1% 3,816,567 2,895,729 $177,852 $167,952 $0.0893 $0.0466 $0.0580 C C C

This was recently listed on the Pharmceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

$0.0650

Market information unavailable

135,044 1,069,733 64,144

$288,994 $4,578,457 $1,372,682

$2.1400 $4.2800 $21.4000

C H C H C H

1% 1% 1%

3,957 8,369 7,341 382

$39,570 $284,546 $1,233,288 $160,440

$10.0000 $34.0000 $168.0000 $420.0000

C H C H C H C H

1% 1% 1% 1%

H PCT 1%

1,763,099

$418,736

$0.2375

C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Topotecan Inj 1 mg H PCT 1%

Units

Cost

Unit Subsidy

DV Limit

Comments

Inj 4 mg

H PCT 1%

Tretinoin Cap 10 mg Venlafaxine Tab immediate-release 12.5 mg C H 1%

Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction

H PCT 1%

Tab immediate-release 25 mg

C H

Tab immediate-release 37.5 mg

C H

Tab immediate-release 50 mg

C H

Tab immediate-release 75 mg

C H

Tab immediate-release 100 mg

C H

Vincristine Sulphate Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Vitamin B Complex (BPC, strong) Tab Vitamins (BPC cap strength) Tab Wool Fat with Mineral Oil Lotn hydrous 3% with mineral oil Zidovudine (AZT) Cap 100 mg 47,957 $139,075 $2.9000

+ C H

H PCT 1% H PCT 1%

2,369,926

$57,352

$0.0242

24,790,242

$366,896

$0.0148

10,719,597

$60,030

$0.0056

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Zidovudine (AZT) Oral liq 10 mg per ml Zinc Crm BP Zoledronic Acid Inj 4 mg Inj 5 mg H H 1% 1% 220,121 $2,884 $0.0131 * C 60,246 $17,471 $0.2900

+ C H

Units

Cost

Unit Subsidy

DV Limit

Comments

Metadata

Title

Pharmaceutical Suppliers: Multi-product Tender consultation

Abstract

21 August 2009 2009/10 Multi-product Tender PHARMAC is seeking feedback from pharmaceutical suppliers and interested parties on: · · · A proposal to tender certain pharmaceuticals for sole supply; The draft process and terms and conditions for the Invitation to…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.